A cohort study of MFN2 mutations and phenotypic spectrums in Charcot-Marie-Tooth disease 2A patients

被引:34
|
作者
Choi, B-O [1 ]
Nakhro, K. [2 ]
Park, H. J. [2 ]
Hyun, Y. S. [2 ]
Lee, J. H. [2 ]
Kanwal, S. [3 ]
Jung, S-C. [4 ]
Chung, K. W. [2 ]
机构
[1] Sungkyunkwan Univ, Dept Neurol, Samsung Med Ctr, Sch Med, Seoul, South Korea
[2] Kongju Natl Univ, Dept Biol Sci, Kong Ju 314701, Chungnam, South Korea
[3] COMSATS Inst Informat Technol, Dept Biosci, Sahiwa, Pakistan
[4] Ewha Womans Univ, Mokdong Hosp, Dept Biochem, Sch Med, Seoul 158710, South Korea
关键词
Charcot-Marie-Tooth disease 2A; exome; genotype-phenotype correlation; Korean; mitofusin; 2; GENETIC SUBTYPES; OPTIC ATROPHY; MITOFUSIN-2; NEUROPATHY; MITOCHONDRIA; POPULATION; FREQUENCY; FAMILIES; TYPE-2;
D O I
10.1111/cge.12432
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Charcot-Marie-Tooth disease 2A (CMT2A) is the most common axonal form of peripheral neuropathy caused by a defect in the mitofusin 2 (MFN2) gene, which encodes an outer mitochondrial membrane GTPase. MFN2 mutations result in a large range of phenotypes. This study analyzed the prevalence of MFN2 mutation in Korean families with their assorted phenotypes (607 CMT families and 160 CMT2 families). Direct sequencing of the MFN2 coding exons or whole-exome sequencing has been applied to identify causative mutations. A total of 21 mutations were found in 36 CMT2 families. Comparative genotype-phenotype correlations impacting severity, onset age, and specific symptoms were assessed. Most mutations were seen in the GTPase domain (approximate to 86%). A deletion mutation found in the transmembrane helices is reported for the first time, as well as five novel mutations at other domains. MFN2 mutations made up 5.9% of total CMT families, whereas 22.9% in CMT2 families, of which 27.8% occurred de novo. Interestingly, patient phenotypes ranged from mild to severe even for the same mutation, suggesting other factors influenced phenotype and penetrance. This CMT2A cohort study will be useful for molecular diagnosis and treatment of axonal neuropathy.
引用
收藏
页码:594 / 598
页数:5
相关论文
共 50 条
  • [41] MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics
    Larrea, Delfina
    Pera, Marta
    Gonnelli, Adriano
    Quintana-Cabrera, Ruben
    Akman, H. Orhan
    Guardia-Laguarta, Cristina
    Velasco, Kevin R.
    Area-Gomez, Estela
    Dal Bello, Federica
    De Stefani, Diego
    Horvath, Rita
    Shy, Michael E.
    Schon, Eric A.
    Giacomello, Marta
    HUMAN MOLECULAR GENETICS, 2019, 28 (11) : 1782 - 1800
  • [42] A novel double mutation in cis in MFN2 causes Charcot–Marie–Tooth neuropathy type 2A
    Su-Yeon Park
    So Yeon Kim
    Yoon-Ho Hong
    Sung Im Cho
    Moon-Woo Seong
    Sung Sup Park
    neurogenetics, 2012, 13 : 275 - 280
  • [43] A novel p.Val244Leu mutation in MFN2 leads to Charcot-Marie-Tooth disease type 2
    Yuan Yang
    Ling Li
    Italian Journal of Pediatrics, 42
  • [44] A novel p.Val244Leu mutation in MFN2 leads to Charcot-Marie-Tooth disease type 2
    Yang, Yuan
    Li, Ling
    ITALIAN JOURNAL OF PEDIATRICS, 2016, 42
  • [45] Combined RNA interference and gene replacement therapy targeting MFN2 as proof of principle for the treatment of Charcot-Marie-Tooth type 2A
    Rizzo, Federica
    Bono, Silvia
    Ruepp, Marc David
    Salani, Sabrina
    Ottoboni, Linda
    Abati, Elena
    Melzi, Valentina
    Cordiglieri, Chiara
    Pagliarani, Serena
    De Gioia, Roberta
    Anastasia, Alessia
    Taiana, Michela
    Garbellini, Manuela
    Lodato, Simona
    Kunderfranco, Paolo
    Cazzato, Daniele
    Cartelli, Daniele
    Lonati, Caterina
    Bresolin, Nereo
    Comi, Giacomo
    Nizzardo, Monica
    Corti, Stefania
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (12)
  • [46] MFN2 point mutations occur in 3.4% of Charcot-Marie-Tooth families. An investigation of 232 Norwegian CMT families
    Braathen, Geir J.
    Sand, Jette C.
    Lobato, Ana
    Hoyer, Helle
    Russell, Michael B.
    BMC MEDICAL GENETICS, 2010, 11
  • [47] Charcot-Marie-Tooth Disease Type 2A From Typical to Rare Phenotypic and Genotypic Features
    Bombelli, Francesco
    Stojkovic, Tanya
    Dubourg, Odile
    Echaniz-Laguna, Andoni
    Tardieu, Sandrine
    Larcher, Kathy
    Amati-Bonneau, Patrizia
    Latour, Philippe
    Vignal, Odile
    Cazeneuve, Cecile
    Brice, Alexis
    Leguern, Eric
    JAMA NEUROLOGY, 2014, 71 (08) : 1036 - 1042
  • [48] The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system
    Pich, S
    Bach, D
    Briones, P
    Liesa, M
    Camps, M
    Testar, X
    Palacín, M
    Zorzano, A
    HUMAN MOLECULAR GENETICS, 2005, 14 (11) : 1405 - 1415
  • [49] Mitochondrial coupling defect in fibroblasts from patients with Mfn2-related Charcot-Marie-Tooth type 2a
    Verny, Christophe
    Loiseau, Dominique
    Chevrollier, Arnaud
    Guillet, Virginie
    Pou, Marie Anne
    Malthiery, Yves
    Amati-Bonneau, Patrizia
    Dubas, Frederic
    Reynier, Pascal
    Bonneau, Dominique
    NEUROLOGY, 2007, 68 (12) : A304 - A304
  • [50] MFN2-related Charcot-Marie-Tooth Disease with Atypical Ocular Manifestations
    Nan, Haitian
    Hata, Takanori
    Fukao, Toko
    Fukao, Toshimichi
    Chen, Wanjing
    Kurita, Takafumi
    Natori, Takahiro
    Takiyama, Yoshihisa
    INTERNAL MEDICINE, 2021, 60 (24) : 3969 - 3974